{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:57:08Z","timestamp":1787443028090,"version":"build-2736575974"},"reference-count":45,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are rare atypical parkinsonian syndromes, characterized by motor and cognitive symptoms. Their clinical diagnosis is challenging because there are no established biomarkers. Dysregulation of microRNAs (miRNAs\/miRs) has been reported to serve an important role in neurodegenerative diseases. However, the miRNA profiles of MSA and PSP patients are rarely reported. The aim of this study was to critically review the role of miRNAs as diagnostic biomarkers to differentiate these atypical parkinsonian disorders and their role in disease pathogenesis. Materials and Methods: A systematic literature search of PubMed was conducted up to February 2022 according the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: A total of 15 studies were analyzed. Three studies have shown that miR-9-3p, miR-19a, miR-19b, and miR-24 are potential biomarkers for MSA. In two studies, miR-132 was downregulated, whereas miR-147a and miR-518e were upregulated in the brain tissue of PSP patients. Conclusions: The potential of miRNA is still uncertain as a potential differential diagnostic marker to identify these disorders. Pre-analytical and analytical factors of included studies were important limitations to justify the introduction of miRNAs into clinical practice.<\/jats:p>","DOI":"10.3390\/medicina58040483","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T21:29:36Z","timestamp":1648416576000},"page":"483","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["MicroRNA as Candidate Biomarkers in Atypical Parkinsonian Syndromes: Systematic Literature Review"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-8711","authenticated-orcid":false,"given":"Anastasia","family":"Bougea","sequence":"first","affiliation":[{"name":"1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, 72-74 Vassilisis Sofia\u2019s Avenue, 11528 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/WCO.0000000000000581","article-title":"Progressive supranuclear palsy and multiple system atrophy: Clinicopathological concepts and therapeutic challenges","volume":"31","author":"Respondek","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fneur.2020.00180","article-title":"Progressive Supranuclear Palsy-Parkinsonism Predominant (PSP-P)-A Clinical Challenge at the Boundaries of PSP and Parkinson\u2019s Disease (PD)","volume":"11","author":"Alster","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autneu.2017.10.007","article-title":"Diagnosis of multiple system atrophy","volume":"211","author":"Palma","year":"2018","journal-title":"Auton. Neurosci. Basic Clin."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 69, 89\u201395.","DOI":"10.1067\/mcp.2001.113989"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/978-3-319-57193-5_20","article-title":"Biomarkers in Neurodegenerative Diseases","volume":"15","author":"Jeromin","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-021-00430-x","article-title":"Moving fluid biomarkers for Alzheimer\u2019s disease from research tools to routine clinical diagnostics","volume":"16","author":"Zetterberg","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"ref_7","first-page":"1117","article-title":"Diagnostic Approach to Atypical Parkinsonian Syndromes","volume":"22","author":"McFarland","year":"2016","journal-title":"Continuum"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"a009258","DOI":"10.1101\/cshperspect.a009258","article-title":"Parkinson\u2019s disease and parkinsonism: Neuropathology","volume":"2","author":"Dickson","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fnagi.2018.00123","article-title":"Plasma Biomarkers Differentiate Parkinson\u2019s Disease From Atypical Parkinsonism Syndromes","volume":"10","author":"Lin","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jns.2017.09.039","article-title":"CSF biomarkers \u03b2-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes","volume":"382","author":"Constantinides","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","article-title":"A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes","volume":"86","author":"Magdalinou","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-021-00775-x","article-title":"The role of noncoding RNAs in Parkinson\u2019s disease: Biomarkers and associations with pathogenic pathways","volume":"28","author":"Kuo","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10571-019-00751-y","article-title":"Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases","volume":"40","author":"Barbagallo","year":"2020","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3389\/fnins.2018.00625","article-title":"Circulating miRNAs as Diagnostic Biomarkers for Parkinson\u2019s Disease","volume":"12","author":"Roser","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ana.25490","article-title":"Meta-analyses identify differentially expressed micrornas in Parkinson\u2019s disease","volume":"85","author":"Schulz","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/mds.27928","article-title":"Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson\u2019s disease","volume":"35","author":"Ravanidis","year":"2020","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/acn3.51146","article-title":"Validation of differentially expressed brain-enriched microRNAs in the plasma of PD patients","volume":"7","author":"Ravanidis","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17455","DOI":"10.18632\/oncotarget.24736","article-title":"miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson\u2019s disease","volume":"9","author":"Correia","year":"2018","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10072-017-2841-9","article-title":"Plasma levels of miR-137 and miR-124 are associated with Parkinson\u2019s disease but not with Parkinson\u2019s disease with depression","volume":"38","author":"Li","year":"2017","journal-title":"Neurol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jbiotec.2011.01.023","article-title":"Identification of blood microRNAs associated to Parkinson\u012ds disease","volume":"152","author":"Margis","year":"2011","journal-title":"J. Biotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., Shill, H., Adler, C., Sabbagh, M., and Villa, S. (2014). Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer\u2019s and Parkinson\u2019s diseases correlate with disease status and features of pathology. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094839"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/ejn.12444","article-title":"Widespread microRNA dysregulation in multiple system atrophy\u2014Disease-related alteration in miR-96","volume":"39","author":"Ubhi","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"632891","DOI":"10.3389\/fnagi.2021.632891","article-title":"Serum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson\u2019s Disease","volume":"13","author":"Vallelunga","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fncel.2014.00156","article-title":"Identification of circulating microRNAs for the differential diagnosis of Parkinson\u2019s disease and Multiple System Atrophy","volume":"8","author":"Vallelunga","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"ref_26","first-page":"852","article-title":"Serum microRNA expression profiling in patients with multiple system atrophy","volume":"17","author":"Kume","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/mds.28143","article-title":"MicroRNA Deregulation in Blood Serum Identifies Multiple System Atrophy Altered Pathways","volume":"35","author":"Bravo","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.1140481","article-title":"A MicroRNA feedback circuit in midbrain dopamine neurons","volume":"317","author":"Kim","year":"2007","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13041-019-0471-2","article-title":"Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson\u2019s disease","volume":"12","author":"Uwatoko","year":"2019","journal-title":"Mol. Brain"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.1007\/s12035-016-0253-0","article-title":"MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson\u2019s Disease and Multiple System Atrophy","volume":"54","author":"Marques","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Schafferer, S., Khurana, R., Refolo, V., Venezia, S., Sturm, E., Piatti, P., Hechenberger, C., Hackl, H., Kessler, R., and Willi, M. (2016). Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150705"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fnmol.2017.00329","article-title":"MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy","volume":"10","author":"Valera","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.18632\/oncotarget.6732","article-title":"miR-183 regulates autophagy and apoptosis in colorectal cancer through targeting of UVRAG","volume":"7","author":"Huangfu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1038\/s41598-017-03887-3","article-title":"Downregulation of blood serum microRNA 29 family in patients with Parkinson\u2019s disease","volume":"7","author":"Bai","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/21541248.2017.1332506","article-title":"Subversion of RAB5-regulated autophagy by the intracellular pathogen Ehrlichia chaffeensis","volume":"10","author":"Rikihisa","year":"2019","journal-title":"Small GTPases"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1093\/hmg\/ddr330","article-title":"MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy","volume":"20","author":"Smith","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10048-016-0480-6","article-title":"microRNA profiling: Increased expression of miR-147a and miR-518e in progressive supranuclear palsy (PSP)","volume":"17","author":"Tatura","year":"2016","journal-title":"Neurogenetics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3892\/mmr.2022.12604","article-title":"A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy","volume":"25","author":"Nonaka","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/mds.27542","article-title":"The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes","volume":"34","author":"Starhof","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.neulet.2016.10.034","article-title":"MicroRNA expression profiles of multiple system atrophy from formalin-fixed paraffin-embedded samples","volume":"635","author":"Wakabayashi","year":"2016","journal-title":"Neurosci. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/aian.AIAN_440_19","article-title":"Clinical Application of Circulating MicroRNAs in Parkinson\u2019s Disease: The Challenges and Opportunities as Diagnostic Biomarker","volume":"23","author":"Ramaswamy","year":"2020","journal-title":"Ann. Indian Acad. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jns.2018.08.032","article-title":"MicroRNAs to differentiate Parkinsonian disorders: Advances in biomarkers and therapeutics","volume":"394","author":"Ramaswamy","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12035-014-8788-4","article-title":"Altered expression of miR-202 in cerebellum of multiple-system atrophy","volume":"51","author":"Lee","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1409","DOI":"10.1002\/wrna.1409","article-title":"Current progress on microRNAs-based therapeutics in neurodegenerative diseases","volume":"8","author":"Pereira","year":"2017","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Owais, S., and Siddique, Y.H. (2022). A Comprehensive Study of miRNAs in Parkinson\u2019s Disease: Diagnostics and Therapeutic Approaches. CNS Neurol. Disord. Drug Targets.","DOI":"10.2174\/1871527321666220111152756"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/4\/483\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:44:06Z","timestamp":1760136246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/4\/483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,26]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["medicina58040483"],"URL":"https:\/\/doi.org\/10.3390\/medicina58040483","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,26]]}}}